- < General Internal Medicine
Author Correction: First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial
By sjmartinez • March 27, 2025
Shen L, Zhang Y, Li Z, Zhang X, Gao X, Liu B, Wang Y, Ba Y, Li N, Zhang R, Zhang J, Chen Y, Chen J, Huang M, Fu Y, Liu M, Liu Z, Zhao J, Li W, Wei J, Li C, Xu N, Guo Z, Cao B, Liu L, Nie P, Wan L, Sheng L, Liu Z, He Y, Gu K, Wu G, Wang W, Zhang F, Qiu W, Guo J, Ying J, Pan H, Xu H, Yuan Y, Bai Y, Wang Z, Xu J, Zhao X, Liu H, Zhang X, Dai W, Xu H, Liu M, Xie L, Tang Y, Jin J, Qu X, Fang X, Huang M, Chen H, Zheng Z, Wang Y, Wang D, Li X, Yu G, Liu H, Zhou Y, Zhong D, Zeng S, Kang M, Wang M, Gao Y, Li W, Wang Z, Zhang M, Zhang J, Li Q, Sun S, Zang A, Lin L, Xie M, Zhuang Z, Zhang T, Yao Z, Lu D, Liu W, Hu M, Wang ZM, Li B, Xia M, Zhang J, Ying X, Pardoll DM, Ji J. Author Correction: First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial. Nat Med. 2025 Mar 26. doi: 10.1038/s41591-025-03666-y. Epub ahead of print. Erratum for: Nat Med. 2025 Jan 22. doi: 10.1038/s41591-024-03450-4. PMID: 40140623.
Related Posts
Bergerot CD, Bergerot PG, Razavi M, Vinicius da Silva França M, Gomes da Silva JR, Cerveira JA, Fuzita WH, Marques Dos Anjos G, Ferrari R,[...]
Delarmente B, Romanov A, Cui M, Tseng CH, Craff M, Skinner D, Hadfield M, Sarkisian CA, Damberg CL, Fendrick AM, Mafi JN. Impact of telemedicine[...]
Oparaugo NC, Cadavona J, Delshad SD. A Rare Case of Pneumomediastinum and Subcutaneous Emphysema Secondary to Recreational Nitrous Oxide Inhalation. Cureus. 2025 Jul 19;17(7):e88331. doi:[...]
